肿瘤组织非依赖的术前循环肿瘤DNA检测在早期非小细胞肺癌中的临床价值
该研究分析了895例EGFR及间变性淋巴瘤激酶野生型、临床I或II期非小细胞肺癌患者的术前血浆样本,评估基于甲基化的肿瘤组织非依赖游离DNA检测的预后价值。结果显示,临床I期肺腺癌患者术前ctDNA检出率为13%(55/414),且与较差的无复发生存相关(2年无复发生存率69%对91%,log-rank p<0.001),并预测术后发现国际肺癌研究协会3级肿瘤及病理TNM分期上调。
要点
- 临床I期肺腺癌术前ctDNA检出率13%(55/414),与较差无复发生存相关(2年69%对91%,p<0.001)。
- 术前ctDNA检出可预测术后国际肺癌研究协会3级肿瘤及病理TNM分期上调(均p<0.001)。
- 术前ctDNA检出与肿瘤程序性死亡配体1高表达强相关(阳性率28%对55%,p<0.001)。
核心结论
- 研究结果支持将ctDNA检测整合到早期非小细胞肺癌的常规诊断流程中,无需肿瘤组织分析,并有助于识别可能从新辅助免疫检查点抑制剂等创新治疗中获益的高危患者。
研究设计与样本
- 研究分析了895例EGFR及间变性淋巴瘤激酶野生型、临床I或II期非小细胞肺癌患者的术前血浆样本,评估基于甲基化的肿瘤组织非依赖游离DNA检测的预后意义。
主要发现
- 临床I期肺腺癌患者术前ctDNA检出率为13%(55/414),与较差的无复发生存相关(2年无复发生存率69%对91%,log-rank p<0.001),接近临床II期肺腺癌的水平。
- 术前ctDNA检出在临床II期肺腺癌或非肺腺癌患者中无预后价值。
- 在肺腺癌中,肿瘤体积与正电子发射断层扫描摄取程度交互预测术前ctDNA检出。
- 术前ctDNA检出可预测术后发现国际肺癌研究协会3级肿瘤(p<0.001)及病理TNM分期上调(p<0.001)。
- 术前ctDNA检出与肿瘤程序性死亡配体1高表达强相关(阳性率28%对55%,p<0.001),识别出可能从抗程序性死亡配体1治疗中获益的亚组。
临床怎么用
- 作者认为,研究结果支持将ctDNA检测整合到早期非小细胞肺癌的常规诊断流程中,无需肿瘤组织分析。
- 作者认为,ctDNA检测在识别可能从新辅助免疫检查点抑制剂等创新治疗中获益的高危患者方面具有临床实用性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The use of tumor-informed circulating tumor DNA (ctDNA) testing in patients with early-stage disease before surgery is limited, mainly owing to restricted tissue access and extended turnaround times. This study aimed to evaluate the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in a large cohort of patients with resected NSCLC. METHOD: We analyzed presurgical plasma samples from 895 patients with EGFR and anaplastic lymphoma kinase-wild-type, clinical stage I or II NSCLC. The ctDNA status was evaluated for its prognostic significance in relation to tumor volume, metabolic activity, histologic diagnosis, histologic subtypes, and clinical-to-pathologic TNM upstaging. RESULTS: Presurgical ctDNA detection was observed in 55 of 414 patients (13%) with clinical stage I lung adenocarcinoma (LUAD) and was associated with poor recurrence-free survival (2-year recurrence-free survival 69% versus 91%; log-rank p < 0.001), approaching that of clinical stage II LUAD. Presurgical ctDNA detection was not prognostic in patients with clinical stage II LUAD or non-LUAD. Within LUAD, tumor volume and positron emission tomography avidity interacted to predict presurgical ctDNA detection. Moreover, presurgical ctDNA detection was predictive of the postsurgical discovery of International Association for the Study of Lung Cancer grade 3 tumors (p < 0.001) and pathologic TNM upstaging (p < 0.001). Notably, presurgical ctDNA detection strongly correlated with higher programmed death-ligand 1 expression in tumors (positive rates 28% versus 55%, p < 0.001), identifying a subgroup likely to benefit from anti-programmed death-ligand 1 therapies. CONCLUSION: These findings support the integration of ctDNA testing into routine diagnostic workflows in early-stage NSCLC without the need for tumor tissue profiling. Furthermore, it is clinically useful in identifying patients at high risk who might benefit from innovative treatments, including neoadjuvant immune checkpoint inhibitors.
引用
- Hong TH, Hwang S, Dasgupta A, et al. Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC. J Thorac Oncol. 2024. PMID: 38992468. doi:10.1016/j.jtho.2024.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。